Kneeland Youngblood, M.D., Chairman of the Board
Kneeland has extensive investment experience, having served from 1993 to 1999 on the board of the $100 billion Teacher Retirement system of Texas (TRS). In his capacity as a trustee, he was actively involved in hiring investment advisors, determining asset allocations and formulating investment/benefit policies. He served as chairman of the Fund's Real Estate Committee, where he directed a major restructuring of the $1.4 billion portfolio. He also served on the Board of Directors and developed direct private equity experience with the Texas Growth Fund, a $500 million private equity fund providing growth and expansion capital. Mr. Youngblood is also a Chairman of the board of the American Beacon Funds, a $20 billion investment affiliate of American Airlines. Mr. Youngblood's other board memberships include: Burger King, Starwood Hotels and Resorts and the City of Dallas Employee Retirement System. He is also a Director Emeritus of iStar Financial, a NYSE publicly traded REIT, and a Director Emeritus of the U.S. Enrichment Corporation. Mr. Youngblood is a founder of Pharos Capital Group. He is a graduate of Princeton University and the University of Texas Southwestern Medical School, and is a member of the Council on Foreign Relations.
Michael V. Mullen, President and Chief Executive Officer
Mike is an experienced operations and finance executive with substantial experience in the areas of laboratory sciences, finance and accounting. Mr. Mullen has been employed with the company for over six years in several different capacities. Prior to being appointed to President and Senior Executive Officer, he served as the company’s Chief Financial Officer and Controller where he managed finance, accounting, information technology, billing, reimbursement, and human resources, and he was heavily involved with the commercial side of the company’s business. He holds dual degrees in accounting and laboratory science.
Robert Shufflebarger, Chief Operating Officer
Bob has more than 20 years of experience with life science and technology companies in areas of operations, finance, and marketing. He joined Atherotech in 2000 as one of the first 15 employees and led the scale-up of operations including increasing capacity more than 100 fold. Prior to Atherotech, Bob managed marketing and business development activities for Southern Research Institute, a contract research organization based in Birmingham, AL. He also worked at Southern Biotechnology Associates and at Avanti Polar Lipids, both privately held specialty chemical manufacturers in Birmingham. Bob holds a B.S. in Chemistry from Birmingham-Southern College and an MBA from Duke University.
Scott Rezek, Chief Commercial Officer
Scott has lead sales and marketing initiatives for several industries including health care and technology. Prior to Atherotech, Scott managed a $300M global sales channel at Invitrogen, now Life Technologies (NASDAQ: LIFE), a global biotechnology tools company. Before Invitrogen, Scott worked at San Francisco-based retailer Williams-Sonoma and at Course Technology, a Boston-based publishing subsidiary of the Thomson Corporation. Scott started his professional career as an Account Executive providing account management and overall client support for clients like Sony and Digital/Compaq. He holds a bachelor's from the University of West Florida and a master's from Auburn University.
Jennifer Mason, V.P. of Clinical Operations
Ms. Mason is a member of the American College of Cardiology and the Preventive Cardiovascular Nurses Association. She is the lead author of a review paper, "Gamma Glutamyl Transferase: A Novel Cardiovascular Risk Biomarker" published in the journal, Preventive Cardiology. Mason is responsible for the disease management and clinician services departments at Atherotech, She is also responsible for developing programs to educate the public and health care professionals about Atherotech’s line of cardiometabolic tests.
Ms. Mason comes to Atherotech with eight years experience in the advanced lipid profile market. As a clinician, she brings practical experience in cardiology and heart disease management with her to Atherotech.
Michael E. Cobble, MD, Chief Medical Officer
Mike is a board certified clinical lipidologist and fellow of the National Lipid Association. He runs a private practice in Salt Lake City where he has lived for more than 20 years and focuses on dyslipidemia, diabetes, cardiovascular diseases (CV), hypertension and primary care medicine. Cobble’s practice is also currently a referral clinic for the Harvard Bipolar Research Group encompassing mood and behavior care. He is the director of the Canyons Medical Center and on the board of directors for the Utah Healthy Living Foundation. Along with clinical patient care, Cobble is engaged with clinical research and medical education and is a member of the American Academy of Family Practice, the National Lipid Association, and the American Society of Hypertension. His published articles include topics on pathophysiology and treatment of diabetes. Cobble graduated with honors from the family practice program medical school/residency at The University of Utah School of Medicine. A large part of his practice involves cardiovascular risk assessments, vascular imaging, and the implementation of CV risk reduction strategies.
Eliot A. Brinton, M.D., Medical Advisory Board
Dr. Brinton obtained his M.D. from the University of Utah, trained in Internal Medicine at Duke University, and in Endocrinology at the University of Washington. He has been on the faculty of the Rockefeller University, Wake Forest University, and the University of Arizona. He served for seven years as Chief of the Section of Metabolism, Endocrinology and Nutrition at the Phoenix VA Medical Center where he was also President of the Phoenix Cross-town Endocrine Society and the Arizona Atherosclerosis Club. Currently, he is Director of the Metabolism Section of Cardiovascular Genetics, and Associate Professor at the University of Utah School of Medicine in Salt Lake City. He is President of the Utah Atherosclerosis Society, President-elect of the Pacific Lipid Association and founding board member of both the National Lipid Association and of the American Board of Clinical Lipidology. He serves on the editorial boards of the Journal of Clinical Lipidology, Lipids Online, the Journal of Managed Care Pharmacy, and Future Lipidology.
Michael H. Davidson, M.D., Medical Advisory Board
Dr. Michael Davidson is a nationally recognized expert on statins, novel lipid-lowering drugs and the reduction of coronary artery disease risk through diet and exercise. He specializes in heart disease prevention--teaching patients to take a proactive approach in managing cardiac risk factors. Dr. Davidson was named one of "The Best Doctors in America" by Best Doctors Inc., and one of "America's Top Physicians" by the Consumers' Research Council of America.
An active researcher, Dr. Davidson participates in both pharmaceutical and nutritional clinical trials. His research includes extensive studies on food additives, dietary supplements and health claim petitions to the U.S. Food and Drug Administration (FDA). Dr. Davidson has coordinated more than 700 clinical trials in preventive cardiology, published more than 200 articles in leading medical journals, and lectured extensively on lipid disorders, nutrition and atherosclerosis. He is also the Executive Medical Director at Radiant Research, Director of Preventive Cardiology and Clinical Professor of Medicine at the University of Chicago Pritzker School of Medicine. In addition, he is Founder, President, and Chief Executive Officer of the Chicago Center for Clinical Research, currently part of Radiant Research. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. Dr. Davidson also served as President of the Midwest Lipid Association and is a Board Member of the National Lipid Association.
Prakash C. Deedwania, M.D., Medical Advisory Board
Dr. Deedwania, MD, is Professor of Medicine at the University of California–San Francisco (UCSF) School of Medicine and is Chief of the Cardiology Division for the VACCHCS/UCSF Program in Fresno. He is also Director of Cardiovascular Research for the UCSF Fresno–Central San Joaquin Valley Medical Education Program. In addition, he is Clinical Professor of Medicine at Stanford University in Palo Alto, and is a fellow of the American College of Cardiology, the American College of Chest Physicians, the Clinical Council of Cardiology and the Cardiopulmonary Council of the American Heart Association, the American Society of Clinical Pharmacology and Therapeutics, and the American College of Physicians. He is currently President, California Chapter of the American Society of Hypertension. Dr. Deedwania is a well recognized leader in Preventive Cardiology, Clinical Lipidology, Diabetes, and Metabolic Syndrome and he is an established expert in the areas of Ischemic Heart Disease, Arrhythmias, and Heart Failure.
Gary H. Gibbons, M.D., Medical Advisory Board
Dr. Gibbons is the endowed Director of the Morehouse Cardiovascular Research Institute, a Professor of Medicine and Chairman of the Department of Physiology. He also serves as Program Director of the Center of Clinical Research Excellence and the NIH T-32 Training Program in Cardiovascular Science. He has been selected as a Robert Wood Johnson Foundation Minority Faculty Development Awardee, a Pew Foundation Biomedical Scholar, an Established Investigator of the American Heart Association (AHA) and was recently elected as member of the Institute of Medicine of the National Academy of Sciences. Dr. Gibbons is a board-certified cardiologist with research training expertise in molecular vascular biology.
Peter H. Jones, M.D., Medical Advisory Board
Dr. Jones, an Associate Professor of Medicine in the Section of Atherosclerosis and Lipid Research at Baylor College of Medicine in Houston, Texas, is also Medical Director for The Methodist Weight Management Center in Houston. He is the lead study physician at Baylor for Look AHEAD, a multicenter, randomized, clinical trial funded by the National Institutes of Health that is studying lifestyle interventions to achieve and maintain weight loss, with a focus on type 2 diabetes. From 1989 to 1998, Dr. Jones was a member of the steering committee for the Air Force Coronary Atherosclerosis Prevention Study. He is a board member and former president (2005-2006) of the National Lipid Association (NLA). Dr. Jones is the author of numerous journal articles and books.
Richard B. Lanman, M.D., Medical Advisory Board
Dr. Lanman graduated Phi Beta Kappa from Stanford University, and obtained his medical degree from Northwestern University. After an internship in internal medicine at the Moffitt Hospital of the University of California San Francisco he completed a psychiatry residency and passed his Board exams in Psychiatry and Neurology. After serving as Chief of Quality at Kaiser Permanente, he became Medical Director of San Jose Medical Group. Chief Medical Officer at Atherotech and then diaDexus, Inc., Dr. Lanman has broad experience in cardiovascular diagnostics testing. Currently he is Chief Medical Officer at Veracyte, Inc. a molecular diagnostics company applying genomics to the diagnosis of various cancers.
Charles A. Reasner II, M.D., Medical Advisory Board
Dr. Charles Reasner received his BA from Andrews University in Berrien Springs, Michigan and his medical degree from Loma Linda University School of Medicine in Loma Linda, California. He completed his internship and residency in internal medicine at the USAF Medical Center Keesler at Keesler Air Force Base in Mississippi. He completed a fellowship in endocrinology at Wilford Hall USAF Medical Center, Department of Medicine, Endocrine, and Metabolic Service at Lackland Air Force Base in Texas. He is currently Professor of Medicine in the Department of Medicine, Division of Endocrinology, at the University of Texas Health Science Center and Medical Director at the Texas Diabetes Institute in San Antonio, Texas.
Dr. Reasner is a fellow of the American College of Endocrinology, the American College of Physicians, and the Royal College of Edinburgh. He is on the editorial board of the British Journal of Diabetes and Vascular Diseases, and is Editor of the Journal Practical Diabetology.
Peter P. Toth, M.D., Ph.D., Medical Advisory Board
Dr. Toth is in private practice at Sterling Rock Falls Clinic multispecialty physician group in Sterling, Ill., where he serves as Director of Preventive Cardiology. Dr. Toth is also Clinical Associate Professor in the Department of Family and Community Medicine at the University of Illinois and Southern Illinois University.
Dr. Toth is a member of the American Medical Association, American Academy of Family Physicians, Illinois Academy of Family Physicians, American Association for the Advancement of Science, Vascular Biology Working Group and the National Lipid Association. He is also a member of the American College of Cardiology, American College of Chest Physicians, American Heart Association and American Society of Hypertension. Dr. Toth serves on numerous editorial boards for lipidology, atherosclerosis and family care publications. He is Associate Editor of the of the Section on Lipids, Lipoproteins, Atherosclerosis, and Coronary Artery Disease in the Year Book of Endocrinology for Elsevier Publishing.
